Whole-Body [18F]-FDG-PET/MRI for Oncology: A Consensus
                    Recommendation

Lale Umutlu; Thomas Beyer; Johannes Stefan Grueneisen; Christoph Rischpler; Harald H. Quick; Patrick Veit-Haibach; Matthias Eiber; Sandra Purz; Gerald Antoch; Sergios Gatidis; Konstantin Nikolaou; Jürgen F. Schaefer; Ivo Rausch; Ken Herrmann; Vorstand der Interdisziplinären AG für Hybride Bildgebung in
                        alphabetischer Reihenfolge:; Vorstand der Deutschen Röntgengesellschaft (DRG) und der Deutschen
                        Gesellschaft für Nuklearmedizin (DGN) in alphabetischer
                        Reihenfolge:

doi:10.1055/a-0830-4453

Nuklearmedizin - NuclearMedicine, Inhaltsverzeichnis

Nuklearmedizin 2019; 191(02): 68-76
DOI: 10.1055/a-0830-4453

Consensus

Whole-Body [18F]-FDG-PET/MRI for Oncology: A Consensus Recommendation ^[*]

Konsensempfehlungen zur Anwendung der Ganzkörper [18F]-FDG-PET/MRT in der onkologischen Bildgebung

Lale Umutlu

¹Department of Diagnostic and Interventional Radiology and Neuroradiology, University-Hospital Essen, Germany

,

Thomas Beyer

²QIMP Group, Centre for Medical Imaging and Biomedical Engineering, Medical University of Vienna, Austria

,

Johannes Stefan Grueneisen

¹Department of Diagnostic and Interventional Radiology and Neuroradiology, University-Hospital Essen, Germany

,

Christoph Rischpler

³Department of Nuclear Medicine, University-Hospital Essen, Germany

,

Harald H. Quick

⁴High-Field- and Hybrid-MR-Imaging, University-Hospital Essen, Germany

,

Patrick Veit-Haibach

⁵Joint Department of Medical Imaging, University of Toronto, Canada

,

Matthias Eiber

⁶Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University of Munich, Germany

,

Sandra Purz

⁷Department of Nuclear Medicine, University of Leipzig, Germany

,

Gerald Antoch

⁸Department of Diagnostic and Interventional Radiology, University Düsseldorf, Medical Faculty, Düsseldorf, Germany

,

Sergios Gatidis

⁹Department of Diagnostic and Interventional Radiology, University-Hospital Tübingen, Germany

,

Konstantin Nikolaou

⁹Department of Diagnostic and Interventional Radiology, University-Hospital Tübingen, Germany

,

Jürgen F. Schaefer

⁹Department of Diagnostic and Interventional Radiology, University-Hospital Tübingen, Germany

,

Ivo Rausch

²QIMP Group, Centre for Medical Imaging and Biomedical Engineering, Medical University of Vienna, Austria

,

Ken Herrmann

³Department of Nuclear Medicine, University-Hospital Essen, Germany

,

Vorstand der Interdisziplinären AG für Hybride Bildgebung in alphabetischer Reihenfolge:

,

Vorstand der Deutschen Röntgengesellschaft (DRG) und der Deutschen Gesellschaft für Nuklearmedizin (DGN) in alphabetischer Reihenfolge:

› Institutsangaben

Abstract

Combined PET/MR imaging (PET/MRI) was proposed for patient management in 2006 with first commercial versions of integrated whole-body systems becoming available as of 2010. PET/MRI followed the prior evolution of hybrid imaging as attested by the successful adoption of combined PET/CT and SPECT/CT since the early 2000 s. Today, around 150 whole-body PET/MRI systems have become operational worldwide. One of the main application fields of PET/MRI is oncologic imaging. Despite the increasing use of PET/MRI, little governance regarding standardized PET/MRI protocols has been provided to date. Standardization and harmonization of imaging protocols is, however, mandatory for efficient on-site patient management and multi-center studies. This document summarizes consensus recommendations on key aspects of patient referral and preparation, PET/MRI workflow and imaging protocols, as well as reporting strategies for whole-body [18F]-FDG-PET/MRI. These recommendations were created by early adopters and key experts in the field of PET, MRI and PET/MRI. This document is intended to provide guidance for the harmonization and standardization of PET/ MRI today and to support wider clinical adoption of this imaging modality for the benefit of patients.

Citation Format:

Umutlu L, Beyer T, Grueneisen JS et al. Whole-Body [18F]-FDG-PET/MRI for Oncology: A Consensus Recommendation. Nuklearmedizin 2019, 58: 1–9

Zusammenfassung

Nach initialen Plänen zur Einführung integrierter PET/MRTSysteme im Jahre 2006 standen 2010 die ersten kommerziell erwerbbaren Scanner für die klinische Anwendung am Patienten zur Verfügung. Sie folgten damit früheren, bereits etablierten hybriden Bildgebungsmodalitäten, wie der PET/CT und SPECT/CT, bei denen der Vorteil einer kombinierten Analyse molekularer und anatomischer Parameter zur Beantwortung onkologischer Fragestellungen gezeigt werden konnte. Bis dato wurden weltweit ca. 150 PET/MRT-Systeme in Kliniken, Praxen und diversen Forschungsinstitutionen installiert. Anhand der aktuellen Studienlage lässt sich die onkologische Diagnostik weiterhin als Hauptanwendungsgebiet erkennen. Aufgrund der zunehmenden Anwendung der PET/MRT in der Patientenversorgung besteht nun die Notwendigkeit einer Anpassung der Arbeitsabläufe an die Anforderungen des klinischen Alltags sowie einer Standardisierung der Untersuchungsprotokolle an die spezifischen medizinischen Fragestellungen. In dem vorliegenden Manuskript werden Konsensempfehlungen für die Indikationsstellung und Vorbereitung des Patienten sowie die Durchführung und Interpretation einer PET/MRT-Untersuchung dargestellt. Darüber hinaus werden Untersuchungsprotokolle zur Anwendung der Ganzkörper [18F]-FDG-PET/MRT zusammengefasst. Diese Empfehlungen wurden durch Experten in den Bereichen der PET, MRT und PET/MRT-Bildgebung zusammengestellt. Sie sollen zur Standardisierung der [18F]-FDG-PET/MRT-Diagnostik onkologischer Patienten und zu einer breiteren klinischen Akzeptanz dieser Bildgebungsmodalität zum Wohle der Patienten beitragen.

Key words

PET/MRI - oncology - consensus recommendations - whole-body imaging - hybrid imaging

Volltext

Referenzen

References
1 Beyer T, Freudenberg LS, Czernin J. et al. The future of hybrid imaging-part 3: PET/MR, small-animal imaging and beyond. Insights Imaging 2011; 2: 235-246 doi:10.1007/s13244–011–0085–4
2 Gambhir SS, Czernin J, Schwimmer J. et al. A tabulated summary of the FDG PET literature. J Nucl Med 2001; 42: 1S-93S
3 Smith TA. FDG uptake, tumour characteristics and response to therapy: a review. Nucl Med Commun 1998; 19: 97-105
4 Kapoor V, McCook BM, Torok FS. An introduction to PET-CT imaging. Radiographics 2004; 24: 523-543 doi:10.1148/rg.242025724
5 Petersen H, Holdgaard PC, Madsen PH. et al. FDG PET/CT in cancer: comparison of actual use with literature-based recommendations. Eur J Nucl Med Mol Imaging 2016; 43: 695-706 doi:10.1007/s00259–015–3217–0
6 Boellaard R, Delgado-Bolton R, Oyen WJ. et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging 2015; 42: 328-354 doi:10.1007/s00259–014–2961-x
7 Pooley RA. AAPM/RSNA physics tutorial for residents: fundamental physics of MR imaging. Radiographics 2005; 25: 1087-1099 doi:10.1148/rg.254055027
8 Kuhl CK, Gieseke J, von Falkenhausen M. et al. Sensitivity encoding for diffusion-weighted MR imaging at 3.0 T: intraindividual comparative study. Radiology 2005; 234: 517-526 doi:10.1148/radiol.2342031626
9 Nensa F, Beiderwellen K, Heusch P. et al. Clinical applications of PET/MRI: current status and future perspectives. Diagn Interv Radiol 2014; 20: 438-447 doi:10.5152/dir.2014.14008
10 Pichler BJ, Kolb A, Nagele T. et al. PET/MRI: paving the way for the next generation of clinical multimodality imaging applications. J Nucl Med 2010; 51: 333-336 doi:10.2967/jnumed.109.061853
11 Wehrl HF, Sauter AW, Divine MR. et al. Combined PET/MR: a technology becomes mature. J Nucl Med 2015; 56: 165-168 doi:10.2967/jnumed.114.150318
12 Wehrl HF, Wiehr S, Divine MR. et al. Preclinical and Translational PET/MR Imaging. J Nucl Med 2014; 55: 11S-18S doi:10.2967/jnumed.113.129221
13 Ziegler SI, Pichler BJ, Boening G. et al. A prototype high-resolution animal positron tomograph with avalanche photodiode arrays and LSO crystals. Eur J Nucl Med 2001; 28: 136-143
14 Schlemmer HP, Pichler BJ, Schmand M. et al. Simultaneous MR/PET imaging of the human brain: feasibility study. Radiology 2008; 248: 1028-1035 doi:10.1148/radiol.2483071927
15 Spick C, Herrmann K, Czernin J. 18F-FDG PET/CT and PET/MRI Perform Equally Well in Cancer: Evidence from Studies on More Than 2,300 Patients. J Nucl Med 2016; 57: 420-430 doi:10.2967/jnumed.115.158808
16 Czernin J, Ta L, Herrmann K. Does PET/MR Imaging Improve Cancer Assessments? Literature Evidence from More Than 900 Patients. J Nucl Med 2014; 55: 59S-62S doi:10.2967/jnumed.114.141838
17 Bailey DL, Pichler BJ, Guckel B. et al. Combined PET/MRI: Global Warming-Summary Report of the 6th International Workshop on PET/MRI, March 27–29, 2017, Tubingen, Germany. Mol Imaging Biol 2018; 20: 4-20 doi:10.1007/s11307–017–1123–5
18 Sawicki LM, Grueneisen J, Schaarschmidt BM. et al. Evaluation of (1)(8)F-FDG PET/MRI, (1)(8)F-FDG PET/CT, MRI, and CT in whole-body staging of recurrent breast cancer. Eur J Radiol 2016; 85: 459-465 doi:10.1016/j.ejrad.2015.12.010
19 Schaarschmidt BM, Grueneisen J, Heusch P. et al. Does 18F-FDG PET/MRI reduce the number of indeterminate abdominal incidentalomas compared with 18F-FDG PET/CT?. Nucl Med Commun 2015; 36: 588-595 doi:10.1097/MNM.0000000000000298
20 Queiroz MA, Kubik-Huch RA, Hauser N. et al. PET/MRI and PET/CT in advanced gynaecological tumours: initial experience and comparison. Eur Radiol 2015; 25: 2222-2230 doi:10.1007/s00330–015–3657–8
21 Fendler WP, Czernin J, Herrmann K. et al. Variations in PET/MRI Operations: Results from an International Survey Among 39 Active Sites. J Nucl Med 2016; 57: 2016-2021 doi:10.2967/jnumed.116.174169
22 Krause BJ, Beyer T, Bockisch A. et al. [FDG-PET/CT in oncology. German Guideline]. Nuklearmedizin 2007; 46: 291-301
23 Delbeke D, Coleman RE, Guiberteau MJ. et al. Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. J Nucl Med 2006; 47: 885-895
24 Wagenknecht G, Kaiser HJ, Mottaghy FM. et al. MRI for attenuation correction in PET: methods and challenges. MAGMA 2013; 26: 99-113 doi:10.1007/s10334–012–0353–4
25 Keller SH, Holm S, Hansen AE. et al. Image artifacts from MR-based attenuation correction in clinical, whole-body PET/MRI. MAGMA 2013; 26: 173-181 doi:10.1007/s10334–012–0345–4
26 European Society of Urogenital Radiology (ESUR). ESUR Guidelines: 10.0 Contrast Media Safety Guidelines. 2018 Avalable from: http://www.esur.org/esur-guidelines/ In
27 European Medicines Agency (EMA). Gadolinium containing contrast agents - Assessment report - EMEA/H/A-31/1437. 2017 Available from: https://www.ema.europa.eu/documents/referral/gadolinium-article-31-referral-assessment-report_en.pdf
28 Sammet S. Magnetic resonance safety. Abdom Radiol (NY) 2016; 41: 444-451 doi:10.1007/s00261–016–0680–4
29 Leitlinienreport zur DGN-Handlungsempfehlung (S1-Leitlinie). Nuklearmedizinische Bildgebung. Stand: 01/2015 - AWMF-Registernummer: 031–030. Available from: https://www.awmf.org/leitlinien/detail/ll/031–030.html In
30 Shellock FG. Reference Manual for Magnetic Resonance Safety, Implants and Devices 2018. Shellock R & D Services; 2018
31 Kinahan PE, Townsend DW, Beyer T. et al. Attenuation correction for a combined 3D PET/CT scanner. Med Phys 1998; 25: 2046-2053 doi:10.1118/1.598392
32 Quick HH. Integrated PET/MR. J Magn Reson Imaging 2014; 39: 243-258 doi:10.1002/jmri.24523
33 Martinez-Moller A, Souvatzoglou M, Delso G. et al. Tissue classification as a potential approach for attenuation correction in whole-body PET/MRI: evaluation with PET/CT data. J Nucl Med 2009; 50: 520-526 doi:10.2967/jnumed.108.054726
34 Paulus DH, Quick HH, Geppert C. et al. Whole-Body PET/MR Imaging: Quantitative Evaluation of a Novel Model-Based MR Attenuation Correction Method Including Bone. J Nucl Med 2015; 56: 1061-1066 doi:10.2967/jnumed.115.156000
35 Schulz V, Torres-Espallardo I, Renisch S. et al. Automatic, three-segment, MR-based attenuation correction for whole-body PET/MR data. Eur J Nucl Med Mol Imaging 2011; 38: 138-152 doi:10.1007/s00259–010–1603–1
36 Beyer T, Lassen ML, Boellaard R. et al. Investigating the state-of-the-art in whole-body MR-based attenuation correction: an intra-individual, inter-system, inventory study on three clinical PET/MR systems. MAGMA 2016; 29: 75-87 doi:10.1007/s10334–015–0505–4
37 Samarin A, Burger C, Wollenweber SD. et al. PET/MR imaging of bone lesions--implications for PET quantification from imperfect attenuation correction. Eur J Nucl Med Mol Imaging 2012; 39: 1154-1160 doi:10.1007/s00259–012–2113–0
38 Yang J, Jian Y, Jenkins N. et al. Quantitative Evaluation of Atlas-based Attenuation Correction for Brain PET in an Integrated Time-of-Flight PET/MR Imaging System. Radiology 2017; 284: 169-179 doi:10.1148/radiol.2017161603
39 Yang J, Wiesinger F, Kaushik S. et al. Evaluation of Sinus/Edge-Corrected Zero-Echo-Time-Based Attenuation Correction in Brain PET/MRI. J Nucl Med 2017; 58: 1873-1879 doi:10.2967/jnumed.116.188268
40 Koesters T, Friedman KP, Fenchel M. et al. Dixon Sequence with Superimposed Model-Based Bone Compartment Provides Highly Accurate PET/MR Attenuation Correction of the Brain. J Nucl Med 2016; 57: 918-924 doi:10.2967/jnumed.115.166967
41 Oehmigen M, Lindemann ME, Gratz M. et al. Impact of improved attenuation correction featuring a bone atlas and truncation correction on PET quantification in whole-body PET/MR. Eur J Nucl Med Mol Imaging 2018; 45: 642-653 doi:10.1007/s00259–017–3864–4
42 Elschot M, Selnaes KM, Johansen H. et al. The Effect of Including Bone in DIXON-based Attenuation Correction for (18)F-fluciclovine PET/MRI of Prostate Cancer. J Nucl Med. 2018 doi:10.2967/jnumed.118.208868. doi:10.2967/jnumed.118.208868
43 Drzezga A, Souvatzoglou M, Eiber M. et al. First clinical experience with integrated whole-body PET/MR: comparison to PET/CT in patients with oncologic diagnoses. J Nucl Med 2012; 53: 845-855 doi:10.2967/jnumed.111.098608
44 Boellaard R, Quick HH. Current image acquisition options in PET/MR. Semin Nucl Med 2015; 45: 192-200 doi:10.1053/j.semnuclmed.2014.12.001
45 Brendle C, Schmidt H, Oergel A. et al. Segmentation-based attenuation correction in positron emission tomography/magnetic resonance: erroneous tissue identification and its impact on positron emission tomography interpretation. Invest Radiol 2015; 50: 339-346 doi:10.1097/RLI.0000000000000131
46 Nuyts J, Bal G, Kehren F. et al. Completion of a truncated attenuation image from the attenuated PET emission data. IEEE Trans Med Imaging 2013; 32: 237-246 doi:10.1109/TMI.2012.2220376
47 Nuyts J, Dupont P, Stroobants S. et al. Simultaneous maximum a posteriori reconstruction of attenuation and activity distributions from emission sinograms. IEEE Trans Med Imaging 1999; 18: 393-403 doi:10.1109/42.774167
48 Blumhagen JO, Braun H, Ladebeck R. et al. Field of view extension and truncation correction for MR-based human attenuation correction in simultaneous MR/PET imaging. Med Phys 2014; 41: 022303 doi:10.1118/1.4861097
49 Blumhagen JO, Ladebeck R, Fenchel M. et al. MR-based field-of-view extension in MR/PET: B0 homogenization using gradient enhancement (HUGE). Magn Reson Med 2013; 70: 1047-1057 doi:10.1002/mrm.24555
50 Lindemann ME, Oehmigen M, Blumhagen JO. et al. MR-based truncation and attenuation correction in integrated PET/MR hybrid imaging using HUGE with continuous table motion. Med Phys 2017; 44: 4559-4572 doi:10.1002/mp.12449
51 Catana C. Motion correction options in PET/MRI. Semin Nucl Med 2015; 45: 212-223 doi:10.1053/j.semnuclmed.2015.01.001
52 Catalano OA, Umutlu L, Fuin N. et al. Comparison of the clinical performance of upper abdominal PET/DCE-MRI with and without concurrent respiratory motion correction (MoCo). Eur J Nucl Med Mol Imaging. 2018 doi:10.1007/s00259–018–4084–2. doi:10.1007/s00259–018–4084–2
53 Gratz M, Ruhlmann V, Umutlu L. et al. Impact of MR-based motion correction on clinical PET/MR data of patients with thoracic pathologies. In proc. ISMRM 2017, Apr 21–27; Honolulu, HI, USA. 2017: 3899
54 Fuin N, Pedemonte S, Catalano OA. et al. PET/MRI in the Presence of Metal Implants: Completion of the Attenuation Map from PET Emission Data. J Nucl Med 2017; 58: 840-845 doi:10.2967/jnumed.116.183343
55 Paulus DH, Quick HH. Hybrid Positron Emission Tomography/Magnetic Resonance Imaging: Challenges, Methods, and State of the Art of Hardware Component Attenuation Correction. Invest Radiol 2016; 51: 624-634 doi:10.1097/RLI.0000000000000289
56 Eanm. Draft guidelines for radiopharmacy. Eur J Nucl Med Mol Imaging 2003; 30: BP63-72
57 Committee EP, Busemann Sokole E, Plachcinska A. et al. Routine quality control recommendations for nuclear medicine instrumentation. Eur J Nucl Med Mol Imaging 2010; 37: 662-671 doi:10.1007/s00259–009–1347-y
58 International Atomic Energy Agency (IAEA). Quality Assurance for PET and PET/CT Systems. 2009 Available from: https://www-pub.iaea.org/books/iaeabooks/8002/Quality-Assurance-for-PET-and-PET-CT-Systems
59 Martinez-Moller A, Eiber M, Nekolla SG. et al. Workflow and scan protocol considerations for integrated whole-body PET/MRI in oncology. J Nucl Med 2012; 53: 1415-1426 doi:10.2967/jnumed.112.109348
60 von Schulthess GK, Veit-Haibach P. Workflow Considerations in PET/MR Imaging. J Nucl Med 2014; 55: 19S-24S doi:10.2967/jnumed.113.129239
61 Kirchner J, Sawicki LM, Suntharalingam S. et al. Whole-body staging of female patients with recurrent pelvic malignancies: Ultra-fast 18F-FDG PET/MRI compared to 18F-FDG PET/CT and CT. PLoS One 2017; 12: e0172553 doi:10.1371/journal.pone.0172553
62 Grueneisen J, Schaarschmidt BM, Heubner M. et al. Implementation of FAST-PET/MRI for whole-body staging of female patients with recurrent pelvic malignancies: A comparison to PET/CT. Eur J Radiol 2015; 84: 2097-2102 doi:10.1016/j.ejrad.2015.08.010
63 Grueneisen J, Sawicki LM, Schaarschmidt BM. et al. Evaluation of a Fast Pro}ocol for Staging Lymphoma Patients with Integrated PET/MRI. PLoS One 2016; 11: e0157880 doi:10.1371/journal.pone.0157880
64 Marth C, Landoni F, Mahner S. et al. Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017; 28: iv72-iv83 doi:10.1093/annonc/mdx220
65 Stegger L, Schafers M, Weckesser M. et al. EANM-ESR white paper on multimodality imaging. Eur J Nucl Med Mol Imaging 2008; 35: 677-680 doi:10.1007/s00259–008–0724–2

Whole-Body [18F]-FDG-PET/MRI for Oncology: A Consensus Recommendation [*]

Whole-Body [18F]-FDG-PET/MRI for Oncology: A Consensus Recommendation ^[*]